Gilead Sciences' (GILD) oral combination therapy of Sofosbuvir and Ledipasvi cleared chronic hepatitis C virus in 64-100% of patients in a Phase II trial called Electron2. The combo was tested with and without Ribavirin.
In another study of Sofosbuvir and GS-5816, the cure rate was 94.8-96.1%. (PR)
See more on Hepatitis C drug studies.